Ann: Appendix 4C - December 2018 Quarterly Report, page-2

Quarterly Business Update Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) is pleased to provide the following update on its business activities for the three-month period to 31 December 2018.       Collaboration agreement signed with US big pharma: deal with Janssen Research & Development, LLC to accelerate diabetic kidney disease and heart disease drug discovery using PromarkerD Production of PromarkerD kit version completed: new PromarkerD immunoassay results presented at 18th Diabetes Technology Meeting in USA Record quarterly revenue: continued strength from Analytical Services contracts resulted in quarterly revenue increasing 42% to exceed $0.5 million PromarkerD test to enter Europe: licence deal with Patia Europe to see PromarkerD test available in Spain Dual technology platform provides more licensing opportunities for PromarkerD R&D for new diagnostic tests: proof of concept studies on-going for endometriosis and Giardia